Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,671,969
  • Shares Outstanding, K 183,649
  • Annual Sales, $ 627,240 K
  • Annual Income, $ -177,030 K
  • EBIT $ -170 M
  • EBITDA $ -109 M
  • 60-Month Beta 0.19
  • Price/Sales 10.82
  • Price/Cash Flow N/A
  • Price/Book 6.49

Options Overview Details

View History
  • Implied Volatility 55.10% ( +1.84%)
  • Historical Volatility 51.77%
  • IV Percentile 39%
  • IV Rank 27.34%
  • IV High 105.05% on 07/12/24
  • IV Low 36.30% on 05/16/24
  • Put/Call Vol Ratio 7.47
  • Today's Volume 381
  • Volume Avg (30-Day) 243
  • Put/Call OI Ratio 1.49
  • Today's Open Interest 8,475
  • Open Int (30-Day) 8,798

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 8
  • High Estimate -0.18
  • Low Estimate -0.42
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -106.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.76 +6.97%
on 03/04/25
38.78 -9.61%
on 03/13/25
-1.96 (-5.30%)
since 02/25/25
3-Month
30.17 +16.18%
on 01/13/25
40.00 -12.38%
on 02/21/25
+2.25 (+6.86%)
since 12/24/24
52-Week
30.17 +16.18%
on 01/13/25
60.87 -42.42%
on 07/25/24
-21.61 (-38.14%)
since 03/25/24

Most Recent Stories

More News
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

LEGN : 35.05 (-3.52%)
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

LEGN : 35.05 (-3.52%)
Oncology Experts Predict 2025 Will Be a Year of Breakthroughs in Treatment and Prevention

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – One of the largest and most advanced cancer research and treatment organizations in the USA, City of Hope,...

ONCY : 0.6347 (+0.86%)
GH : 46.46 (-0.60%)
LEGN : 35.05 (-3.52%)
PSNL : 3.60 (-6.25%)
GRAL : 31.20 (-2.89%)
ONC.TO : 0.91 (+2.25%)
Legend Biotech CEO to Present Company Updates at 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech's CEO will present company updates at the J.P. Morgan Healthcare Conference on January 14, 2025.Quiver AI SummaryLegend Biotech Corporation announced that CEO Ying Huang, Ph.D., will present...

LEGN : 35.05 (-3.52%)
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LEGN : 35.05 (-3.52%)
Legend Biotech Reports 89% MRD Negativity in CARTITUDE-4 Study for CARVYKTI® in Multiple Myeloma After Three-Year Follow-Up

New data shows CARVYKTI® achieves 89% MRD negativity in multiple myeloma patients, significantly surpassing standard therapies.Quiver AI SummaryLegend Biotech has announced promising results from its...

LEGN : 35.05 (-3.52%)
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

LEGN : 35.05 (-3.52%)
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

LEGN : 35.05 (-3.52%)
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

LEGN : 35.05 (-3.52%)
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

LEGN : 35.05 (-3.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 38.40
2nd Resistance Point 37.88
1st Resistance Point 37.11
Last Price 35.05
1st Support Level 35.82
2nd Support Level 35.30
3rd Support Level 34.53

See More

52-Week High 60.87
Fibonacci 61.8% 49.14
Fibonacci 50% 45.52
Fibonacci 38.2% 41.90
Last Price 35.05
52-Week Low 30.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar